Articles from Marea Therapeutics, Inc.

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that data from its first-in-human Phase 1 study of MAR002 will be highlighted in an oral presentation at the 2026 Annual Meeting of the Endocrine Society (ENDO), being held from June 13-16 in Chicago, IL.

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced positive topline results from its first-in-human Phase 1 study of MAR002, a first-in-class allosteric monoclonal antibody targeting the growth hormone receptor (GHR) for the treatment of acromegaly. The company also highlighted key pipeline milestones expected in 2026 – including for its lead cardiometabolic program, MAR001, a first-in-class, subcutaneously delivered monoclonal antibody designed to block the activity of ANGPTL4, a genetically validated driver of remnant cholesterol and atherosclerotic cardiovascular disease (ASCVD) risk.

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that Josh Lehrer, M.D., chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 10:30 a.m. PT.

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that the first participant has been enrolled in Marea’s Phase 1 study evaluating MAR002 for the treatment of acromegaly.

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that the first patient has been enrolled in Marea’s Phase 2b TYDAL-TIMI 78 study evaluating MAR001 in adults with elevated levels of triglycerides (TG) and remnant cholesterol (RC) at increased risk of atherosclerotic cardiovascular disease (ASCVD). MAR001 is a monoclonal antibody delivered by subcutaneous injection that is designed to block the activity of ANGPTL4, a protein that is highly expressed in adipose tissue. MAR001 is being developed to address unmet risk in patients with ASCVD and persistently elevated levels of TG and RC.

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the presentation of preclinical data on MAR002, a novel growth hormone receptor (GHR) antagonist antibody for the treatment of acromegaly, at the 2025 Annual Meeting of the Endocrine Society (ENDO).

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the appointment of Shishir Gadam, Ph.D., as chief technical officer. Dr. Gadam has extensive experience in the biotechnology industry and brings deep expertise and leadership in biologics development and manufacturing to Marea Therapeutics.

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced an upcoming oral presentation related to MAR002, the company’s potential first-in-class, anti-growth hormone receptor (GHR) antibody being developed for acromegaly, at the 2025 Annual Meeting of the Endocrine Society (ENDO), being held from July 12-15, 2025 in San Francisco, CA.

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the appointment of Charmi Turner as senior vice president, people & culture. Charmi is an experienced life sciences industry human resources executive who brings deep expertise in leadership development and organizational alignment to Marea Therapeutics.

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that positive results from a Phase 2a clinical trial of MAR001 were published in The Lancet entitled “Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies.” The publication follows a recent late-breaking oral presentation of the Phase 2a results at the 93rd EAS Congress and can be accessed here. In addition, Marea announced a publication of MAR001 preclinical results in the peer-reviewed journal eBioMedicine entitled “A Novel ANGPTL4 Inhibitory Antibody Safely Improves Lipid Profiles in Non-Human Primates.” The publication can be accessed here.

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today presented positive data from a Phase 2a clinical trial of MAR001 in a late-breaking oral session at the 93rd European Atherosclerosis Society (EAS) Congress being held May 4-7, 2025 in Glasgow, UK. MAR001 is a first-in-class monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue.

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced two upcoming presentations at the 93rd European Atherosclerosis Society (EAS) Congress being held May 4-7, 2025 in Glasgow, UK.

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases, today announced the formation of a clinical scientific advisory board (SAB) consisting of leading experts in drug development and cardiometabolic diseases.

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardio-endocrine diseases, today provided an update on the company’s recent progress and upcoming milestones for 2025 in advance of the J.P. Morgan 43rd Annual Healthcare Conference, taking place from January 13-16, 2025 in San Francisco, CA.

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases, today announced additions to its management team and board of directors.